17β-Hydroxyandrost-4-en-3-onundecanoat
Undecanoate · andriol · Testosterone 17-undecanoate · Testo U · Test un · Test Unde · Test undeca · BoldenoneUndecanoate
Identifikatoren & physikalische Daten
| CAS No. | 5949-44-0 |
|---|---|
| Summenformel | C30H48O3 |
| Durchschnittliche Molmasse | 456,7 g/mol |
| Monoisotopische Masse | 456,3603454 g/mol |
| SMILES | CCCCCCCCCCC(=O)O[C@H]1CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C |
| InChIKey | UDSFVOAUHKGBEK-CNQKSJKFSA-N |
| PubChem CID | 65157 |
| ChEMBL | CHEMBL2107067 |
| ChEBI | CHEBI:135741 |
| EC No. | 227-712-6 |
| DTXSID | DTXSID90863661 |
| Lokaler Name | 17β-Hydroxyandrost-4-en-3-onundecanoat |
Chemische & physikalische Eigenschaften
| XLogP | 8,5 |
|---|---|
| Polarare Oberfläche (TPSA) | 43,4 |
| H-Brücken-Donoren | 0 |
| H-Brücken-Akzeptoren | 3 |
| Frei drehbare Bindungen | 11 |
| Schwere Atome | 33 |
| Formalladung | 0 |
| Komplexität | 739 |
| Arzneimittel | Pharmaceuticals -> Listed in ZINC15 |
| Löslichkeit | <1 mg/mLDMSO : 10 mg/mL (21.90 mMNeed ultrasonic and warming) |
| Human Drugs | FDA approved drugs -> Active ingredient |
| Endocrine Disruptors | Potential endocrine disrupting compound |
| Schmelzpunkt | 59-61°C |
| Siedepunkt | 550.7±50.0 °C(Predicted) |
| Dichte | 1.03±0.1 g/cm3(Predicted) |
| Lagerbedingungen | Controlled Substance, -20°C Freezer |
| Aggregatzustand | Solid |
| Farbe | White to Off-White |
| InChIKey | UDSFVOAUHKGBEK-JCROKFDDNA-N |
| SMILES | C[C@]12CCC(=O)C=C1CC[C@@]1([H])[C@]3([H])CC[C@H](OC(=O)CCCCCCCCCC)[C@@]3(C)CC[C@]21[H] |&1:1,10,12,16,30,34,r| |
| CAS Datenbank | 5949-44-0(CAS DataBase Reference) |
Sicherheit & Vorschriften
| GHS-Einstufung | DangerH302 (93.3%): Harmful if swallowed [Warning Acute toxicity, oral]P203, P260, P261, P263, P264, P270, P271, P280, P301+P317, P302+P352, P304+P340, P317, P318, P321, P330, P362+P364, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 45 reports by companies from 5 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. |
|---|---|
| Hazard Classes and Categories | Acute Tox. 4 (93.3%) |
| Wassergefährdungsklasse (WGK) | WGK 3 |
| Lagerklasse | 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects |
| Gefahrenklasse | Acute Tox. 4 OralAquatic Acute 1Carc. 2Repr. 1B |
Anwendungen & Verwendung
Beschreibung
Testosterone undecanoate, sold under the brand names Andriol and Aveed among others, is an androgen and anabolic steroid (AAS) medication that is used mainly in the treatment of low testosterone levels in men. which includes hormone therapy for transgender men. It is taken by mouth or given by injection into muscle.Testosterone Undecanoate is the undecanoate ester form of the androgen testosterone, with gonadotropin-secretory inhibiting and hormone replacement activity. As testosterone inhibits the secretion of gonadotropins from the pituitary gland, administration of testosterone decreases the secretion of luteinizing hormone (LH). By inhibiting LH secretion, the growth of Leydig cells, which are normally stimulated by LH to produce testosterone, may be suppressed. In addition, this agent promotes the maintenance of male sex characteristics and can be used for testosterone replacement in hypogonadal males.
Verwenden
Testosterone undecanoate is the ester prodrug of testosterone and has a midchain fatty acid at the 17Beta position. It is available as an intramuscular injection and as an oral capsule, and is indicated for treatment of testosterone deficiency. It should be noted that testosterone undecanoate is only indicated for treatment of hypogonadal conditions with structural or genetic etiologies and should not be used to manage "age-related hypogonadism".